RIZINAL

SALEM
Identification
- Active ingredient (INN)
- LEVOCETIRIZINE DICHLORHYDRATE
- Internal code
- 01 A 054
- Country of Origin
- Algeria
- Pharmaceutical form
- Film-coated Tablet
- Prescription List
- Regulated (List II)
- Packaging
- b/20

DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Levocetirizine is a selective histamine
H 1 antagonist used to treat a variety of allergic symptoms. 2, 3, 4 It is the R enantiomer of cetirizine.
Levocetirizine has greater affinity for the histamine H 1 receptor than cetirizine.
Levocetirizine was granted
FDA approval in 1995.
Indications
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.
It is also used over the counter for a variety of mild allergy symptoms.
Pharmacodynamics
Levocetirizine is a second generation histamine
H 1 antagonist used to treat various allergic symptoms. 2, 3, 4 It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose.
Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.
Absorption
Following a 5 mg oral dose of levocetirizine, a C max of 0.27±0.04 µg/mL with a T max of 0.75±0.50h.
AUC of levocetirizine is 2.31±0.50 µg*h/mL.
Taking levocetirizine with food does not affect the AUC but delays T max by 1.25 hours and lowers C max by 36%.
Volume of Distribution
The volume of distribution of levocetirizine is 0.33±0.02 L/kg.
Metabolism
Levocetirizine is poorly metabolized with 85.8% of an oral dose being excreted as the unchanged drug.
Levocetirizine can be metabolized to a dihydrodiol (M2), an N-oxide (M3), a hydroxymethoxy derivative (M4), a hydroxy derivative (M5), an O-dealkylated derivative (M6), a taurine conjugate (M8), and an N-dealkylated and aromatic hydroxylated derivative (M9).
M5 metabolite can be glucuronidated to form the M1 metabolite and the M9 metabolite can form 4-chloro-4'-hydroxybenzhydryl mercapturates (M10a and M10b).
Hover over products below to view reaction partners Levocetirizine Levocetirizine Dihydrodiol Metabolite (M2) Levocetirizine Hydroxy Metabolite (M5) + Levocetirizine Hydroxymethoxy Metabolite (M4) Levocetirizine N-oxide Metabolite (M3) Levocetirizine Hydroxy Metabolite (M5) Levocetirizine O-glucuronidated Metabolite (M1) Levocetirizine O-dealkylated Metabolite (M6) Levocetirizine Taurine Conjugated Metabolite (M8) Levocetirizine N-dealkylated and Aromatic Hydroxylated Metabolite (M9) Levocetirizine 4-chloro-4'-hydroxybenzhydryl Mercapturate Metabolites (M10a and M10b).
Route of Elimination
hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces.
In the urine, 77% of the dose was recovered as unchanged drug, 0.5% as the M8 and M9 metabolites, 0.4% as the M10a metabolite, 0.4% as the M10b metabolite, 0.3% as the M3 metabolite, 0.3% as the M4 and M5 metabolite, 0.2% as the M2 metabolite, and 0.1% as the M1 metabolite.
In the feces, 9.0% of the dose was recovered as unchanged drug, 1.0% as the M4 and M5 metabolite, and 0.1% as the M1 metabolite.
Half-life
The average half life of levocetirizine is 7.05±1.54 hours.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Patients experiencing an overdose may present with drowsiness.
Children may become agitated and restless before drowsiness.
Patients should be treated with supportive measures.
Dialysis will not assist in removing the drug from the body.
The maximal nonlethal dose in mice and rats is 240 mg/kg.
Warnings
Do not use if you have kidney disease if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine Ask a doctor before use if you have ever had trouble urinating or emptying your bladder When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery Stop use and ask doctor if you have trouble urinating or emptying your bladder an allergic reaction to this product occurs.
Seek medical help right away.
If pregnant or breast-feeding: if breast-feeding: not recommended if pregnant: ask a health professional before use Keep out of reach of children.
In case of overdose, get medical help or contact a Poison Control Center right away.
Dosage & Administration
Directions adults 65 years of age and older ask a doctor adults and children 12-64 years of age take 1 tablet (5 mg) once daily in the evening do not take more than 1 tablet (5 mg) in 24 hours 1/2 tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms children 6-11 years of age take 1/2 tablet (2.5 mg) once daily in the evening do not take more than 1/2 tablet (2.5 mg) in 24 hours children under 6 years of age do not use consumers with kidney disease do not use.